Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Metacrine (NASDAQ:MTCR) has announced that its CEO, Preston Klassen, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Metacrine (NASDAQ:MTCR) has announced that its CEO, Preston Klassen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The event will be accessible via a webcast, which will remain available for 90 days post-conference. Metacrine is focused on developing therapies for liver and gastrointestinal diseases, utilizing its proprietary farnesoid X receptor (FXR) platform. Its leading candidates, MET409 and MET642, are in clinical trials for treating NASH, showcasing promising advancements.
Details
News Market Reaction – MTCR
The recorded move for MTCR in the trading session of this news was -2.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.
A webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 90 days following the conference.
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.